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I ndividuals with urothelial carcinoma usually pres-ent with hematuria and bladder irritation symp-
toms [1].  However,  multiple lymphadenopathy with 
elevated levels of serum S-pancreas-1 antigen (SPan-1) 
is not regarded as an initial presentation of this disease.  
Here we describe the case of a patient with multiple 
metastatic invasive urothelial carcinoma with elevated 
serum SPan-1 and carbohydrate antigen 19-9 (CA19-9) 
levels that was successfully treated with chemotherapy.  
Uroplakin III,  a specific membrane protein of urothelial 
umbrella cells,  was a useful histological marker to detect 
the origin of carcinoma metastases in this case.
Case Presentation
A 62-year-old Japanese man presented with multiple 
swollen lymph nodes and leg edema.  Computed 
tomography (CT) showed the presence of multiple 
lymphadenopathies of the inguinal,  para-aortic,  cervi-
cal,  and mediastinal lymph nodes (Fig. 1).  Although he 
was diagnosed by his previous physician with a meta-
static adenocarcinoma based on the pathological fea-
tures of an inguinal lymph node biopsy,  there was no 
evidence indicating the site of the primary tumor.  He 
was referred to our hospital for further examination.
A blood examination showed a normal complete 
blood cell count,  elevated levels of D-dimer and tumor 
markers including carcinoembryonic antigen (CEA),  
CA19-9 and SPan-1,  and normal urinary test results 
(Table 1).  The inguinal lymph node biopsy results were 
reviewed in our hospital; they revealed atypical epithe-
lial cells with an invasive micropapillary pattern,  which 
indicated a carcinoma metastasis.  There were no malig-
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nant primary lesions in the lung,  gastrointestinal tract,  
or pancreas.  He was transferred to our hospital with a 
diagnosis of adenocarcinoma of unknown origin with 
cancer-associated disseminated intravascular coagula-
tion (DIC) and pulmonary embolism.
Fluorodeoxyglucose positron emission tomography/
CT (FDG-PET/CT) imaging showed multiple FDG 
accumulations in the cervical,  supraclavicular,  medias-
tinal,  para-aortic,  and inguinal lymph nodes.  Further 
histological examination of the lymph nodes was per-
formed.  Immunohistochemical staining results of 
lymph node tumor cells were positive for cytokeratin 
(CK) 7,  negative for CK20,  negative for thyroid tran-
scription factor-1 (TTF-1),  negative for prostate-spe-
cific antigen,  positive for S-100P,  and positive with 
membranous staining pattern for uroplakin III (Fig. 2).  
We then considered the possibility of urothelial cell car-
cinoma.  The urine cytology result was class V,  and 
cystoscopy showed a pedunculated papillary tumor in 
the prostatic urethra.  The histological examination 
revealed that the urethral tumor was an invasive urothe-
lial carcinoma with histological features identical to 
those of the tumor of the inguinal lymph node (Fig. 3).
A diagnosis of invasive urothelial carcinoma of the 
prostatic urethra (cT1N2M1 cStage IV) was made,  and 
the patient underwent chemotherapy with cisplatin 
(70 mg/m2) and gemcitabine (1,000 mg/m2).  The treat-
ment was feasible and after 6 cycles of treatment,  the 
lymph node metastases shrank and the tumor marker 
levels were reduced.  We added four treatment cycles (at 
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(A) (B)
(C) (D)
???? ?　 CT and FDG-PET/CT imaging on admission.  A–C: Swelling of 
multiple mediastinum,  para-aorta,  and bilateral inguinal lymph nodes 
(arrow) was observed on CT images.  D: FDG-PET/CT imaging showed 
FDG accumulation in the mediastinum,  para-aorta,  and iliac artery lymph 
nodes.
80% dose),  expecting further efficacy for the residual 
lesions.  After 10 cycles of treatment,  the patient’s 
CA19-9,  SPan-1,  and CEA levels decreased to normal 
levels,  the systemic lymph node metastases were 
reduced to almost the normal size,  and he achieved a 
complete metabolic response (CMR) on FDG-PET/CT 
(Fig. 4).  He has been well without disease progression 
for over 4 years.
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????? ?　 Laboratory data on admission
Complete blood count
WBC 5,600 /µL
Ne 55 %
Ly 35 %
Mo 6.8 %
Eo 2.8 %
Ba 0.8 %
RBC 395 x104/µL
Hb 13 g/dL
Hematocrit 37 %
Plt 28.2 x104/µL
Coagulation
PT 19 sec
APTT 35 sec
PT-INR 1.8
FDP 24.7 µg/mL
D-dimer 15 µg/mL
Urinalysis
pH 5.5
Protein -
Glucose -
Occult blood -
Sediment negative
Biochemistry
AST 27 U/L
ALT 30 U/L
T-Bil 0.3 mg/dL
ALP 293 U/L
γ-GTP 40 U/L
LDH 263 U/L
Na 139 mEq/L
K 4.4 mEq/L
Cl 108 mEq/L
Ca 8.7 mg/dL
BUN 11 mg/dL
Cre 0.7 mg/dL
CRP 0.4 mg/dL
Tumor marker
β-HCG 1.1 mIU/mL (<0.5)
CYFRA 32.7 ng/mL (<3.5)
CEA 411 ng/mL (<5.0)
AFP 2.8 ng/mL
PSA 1.05 ng/mL
ProGRP 32.5 pg/mL
SLX 67.6 ng/mL (<38)
DUPAN-2 246 U/mL (<150)
SPan-1 5925 U/mL (<30)
CA19-9 40161 U/mL (<37)
(A) (B)
???? ?　 Histological ﬁndings of the inguinal lymph node biopsy specimen A,  A proliferation of atypical epithelial cells showing an invasive 
micro-papillary pattern was detected.  Hematoxylin and eosin (H&E) staining;  B,  Uroplakin III (left) staining was positive with membranous 
staining pattern in atypical epithelial cells.  IHC staining,  S100-P (right) staining was positive in atypical epithelial cells.  IHC staining.
All procedures performed in this case were in accor-
dance with ethical standards of the institution and with 
the Helsinki Declaration and its amendments.
Discussion and Conclusions
Our patient’s case revealed 3 significant clinical 
issues.  First,  urothelial carcinoma can present as mul-
tiple lymphadenopathy without macrohematuria.  
Second,  Span-1 may be a helpful tumor marker for 
urothelial carcinoma.  Third,  some metastatic invasive 
urothelial carcinoma patients with poor prognostic fac-
tors (e.g., elevation of CA19-9 and positive staining for 
uroplakin III) can have long survival after systemic che-
motherapy comprising cisplatin and gemcitabine,  by 
monitoring tumor markers and using FDG-PET.
Our patient presented with multiple lymphadenopathy 
without macrohematuria,  and with elevated levels of 
CA19-9 and SPan-1 accompanied by life-threatening 
DIC and a pulmonary embolism.  In general,  the most 
common symptom of bladder cancer is painless hema-
turia,  which occurs in approximately 85% of patients 
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(A) (B)
???? ?　 Cytoscopic and histological ﬁndings of the bladder tumor.  A, A pedunculated papillary tumor was observed in the prostatic ure-
thra; B, The proliferation of atypical epithelial cells showing an invasive micro-papillary pattern was detected.  H&E staining.
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???? ?　 A,  The clinical course after systemic chemotherapy treatment; B,  The multiple ﬂuorodeoxyglucose accumulations observed by 
PET/CT before systemic chemotherapy (left) disappeared after 10 cycles of treatment (right).
[1],  and if enough urine samples are tested,  > 90% of 
patients with cystoscopically detectable bladder cancer 
have at least microhematuria [2 , 3].  CA19-9,  a carbo-
hydrate antigen related to the Lewis A blood group 
antigen,  is a well-known marker for pancreatic and 
colorectal carcinoma and is being investigated for other 
malignancies including bladder carcinoma [4].  Pall et 
al. reported that the sensitivity of CA19-9 was 29.3% 
when the reference value 37 U/mL was taken as the cut-
off value of serum CA 19-9,  and serum CA19-9 was 
significantly elevated in invasive urothelial carcinoma 
compared to superficial urothelial carcinoma (47.17 ±  
34.43 vs.  16.53 ± 20.13 U/mL,  p < 0.001) [5].
SPan-1 is another carbohydrate antigen related to the 
Lewis A blood group antigen.  Both the CA19-9 and 
SPan-1 assay systems recognize sialyl-lacto-N-fucopen-
taose II to detect malignancies [6].  Compared to 
CA19-9,  SPan-1 is more advantageous in diagnosing 
pancreatic cancer patients with a Lewis-negative pheno-
type [7 , 8].  There are no published studies exploring the 
relationship between SPan-1 and urothelial carcinoma.  
In our patient’s case,  the urine examination showed no 
evidence of hematuria,  and the serum examination 
showed an extreme elevation of CA19-9,  with a SPan-1 
level over 5,000 U/mL,  thus representing a rare clinical 
case.  Hydronephrosis sometimes induces the elevation 
of CA19-9 and Span-1 [9].  In our patient’s case how-
ever,  hydronephrosis was not observed at the timing of 
diagnosis.  Moreover,  his serum CA19-9 and Span-1 
levels markedly decreased as the tumor regressed.  
Collectively,  these results show that both CA19-9 and 
Span-1 were effective tumor markers in this case.  
Further reports are needed to elucidate the relationship 
between the elevation of SPan-1 and the prognosis or 
pathophysiology of urothelial carcinoma.
FDG-PET/CT is not widely used to detect and 
locally stage bladder cancer.  This is because the physio-
logical activity of 18F-FDG,  which is excreted through 
the urinary system,  interferes with the visualization of 
the primary bladder cancer and locoregional lymph 
nodes [10].  Uroplakins,  which are transmembrane 
proteins constituting the asymmetrical unit membrane 
of urothelial umbrella cells,  are useful markers of carci-
noma metastases of uncertain origin [11].  In our 
patient’s case,  uroplakin III staining was positive,  which 
was the key clue to the need for further examination of 
the urinary system,  while FDG-PET could not detect 
the tumor’s primary site.
Elevated CA19-9 and positive staining for uroplakin 
III are related to metastatic urothelial carcinoma,  which 
has a poor prognosis [5 , 11].  A long-term follow-up of 
urothelial carcinoma patients after systemic chemo-
therapy comprising cisplatin and gemcitabine revealed 
a 48-month progression-free survival rate of 9.8% 
[12 , 13].  In recent years,  several research groups have 
reported that FDG-PET/CT can be used successfully for 
the early assessment of the patient’s treatment response 
and the prognostication of bladder cancer [14 , 15].  
Giannatempo et al.  demonstrated that,  compared to 
early CT,  a response after 2 cycles of first-line chemo-
therapy detected by FDG-PET/CT was associated with 
longer progression-free survival and overall survival in 
31 patients with advanced urothelial carcinoma [14].  
Mertens et al.  reported that the presence of extravesical 
FDG-avid lesions on PET/CT was an independent indi-
cator of mortality in 211 patients with muscle-invasive 
bladder carcinoma [15].  Although our patient showed 
significant elevations of CA19-9 and SPan-1,  his multi-
ple lymph node metastases were greatly reduced after 
10 cycles of chemotherapy,  with a decrease of these 
markers to normal levels and the achievement of CMR 
shown by FDG-PET/CT.  Together,  these resulted in 
long survival with no recurrence.  These findings may 
indicate that good responders who achieve a CMR on 
FDG-PET/CT can survive longer,  even with advanced 
urothelial carcinoma.
In conclusion,  urothelial carcinoma can present as 
swelling of multiple lymph nodes without hematuria,  
and the present case demonstrates that uroplakin III was 
useful for an accurate diagnosis.  Some urothelial carci-
nomas without hematuria might be diagnosed as carci-
noma of unknown origin,  and thus there may be more 
cases of systemic invasive urothelial carcinoma than are 
currently recognized.  The immunohistochemical stain-
ing of markers including uroplakin III should be used in 
cases of highly elevated CA19-9 or SPan-1 without evi-
dence of pancreatic or colorectal cancer.
Further reports of similar cases are needed to deter-
mine the prognostic factors for long survival after sys-
temic chemotherapy.
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